![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Publisher: Adis International
ISSN: 1174-5886
Source: Drugs in R&D, Vol.3, Iss.2, 2002-02, pp. : 106-108
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Natalizumab: AN 100226, Anti-4 Integrin Monoclonal Antibody
Drugs in R&D, Vol. 5, Iss. 2, 2004-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
By Vugmeyster Yulia Szklut Pam Wensel David Ross John Xu Xin Awwad Michel Gill Davinder Tchistiakov Lioudmila Warner Garvin
Pharmaceutical Research, Vol. 28, Iss. 7, 2011-07 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Anti-CTLA-4 monoclonal antibody: First report of uveitis: 2 case reports
Reactions Weekly, Vol. 1, Iss. 1042, 2005-01 ,pp. :